Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

This study is testing a new type of immune cell therapy — CAR-NK cells (natural killer cells engineered to target a protein called CD123) — in patients with difficult-to-treat blood cancers: acute myeloid leukemia (AML) or a rare condition called BPDCN. **You may be eligible if:** - You are between 18 and 75 years old - Your cancer cells test positive for the CD123 protein - You have AML or BPDCN that has relapsed (come back) or is not responding to standard treatments - You are in reasonably good health and your heart, kidneys, and liver are functioning adequately - Your expected survival is more than 12 weeks **You may NOT be eligible if:** - You have an uncontrolled active infection - You have active hepatitis B or C, or HIV - You are pregnant or nursing - You recently received chemotherapy, radiation, or other cancer treatments (within a specified window) - You have previously received CAR-T or other similar cell therapies (depending on type) Talk to your doctor to see if this trial is right for you.